Rare cancer hope: genetic tests may match patients to better treatments

NCT ID NCT04504604

Recruiting now Knowledge-focused Sponsor: TargetCancer Foundation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether genetic testing of tumors and blood can help doctors choose better treatments for people with rare cancers. About 400 adults with rare solid tumors or lymphomas will have their tumors genetically analyzed. A team of experts will review the results and recommend personalized therapies. The goal is to see if this approach improves how long patients live without their cancer getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FoundationOne CDx and FoundationOne Liquid CDx (diagnostic tests)
What this could lead to: If successful, this could show that personalized treatment based on genetic testing improves outcomes for people with rare cancers.
What could go wrong: This is an early-stage study with no control group, so results may not prove effectiveness. The approach may not work for all rare cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER OF UNKNOWN PRIMARY SITE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer of unknown primary site cholangiocarcinoma lymphoma Neoplasms, Unknown Primary

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER OF UNKNOWN PRIMARY SITE CHOLANGIOCARCINOMA RARE CANCERS

Contacts and locations

Locations

TargetCancer Foundation
RECRUITING

Cambridge, Massachusetts, 02139, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.